Concept
Monitoring Update
10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE / 3. A Shorter Hospital Stay for Imdelltra
"People starting Imdelltra (tarlatamab) for extensive-stage small cell lung cancer now need 6 to 8 hours of monitoring after each of their first two doses, down from 22 to 24 hours. Patients must still stay within an hour of a medical facility, with a caregiver, for 48 hours after each of those doses."
Related Ideas
- Treatment Access10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways
- September Options10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Key Takeaways
- Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 2. Hyrnuo as a First Treatment for HER2-Mutant Lung Cancer
- Testing10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 2. Hyrnuo as a First Treatment for HER2-Mutant Lung Cancer
- Cancer Images10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · Related to this article
- Hyrnuo Approval10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · References:
- Treatment Access10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 6. Bexlutry for Neuroendocrine Tumors
- Treatment Access10 Cancer Treatment Approvals From September 2026 and What They Mean for You | CURE · 8. Bravnetsa for Neuroendocrine Tumors